www.merckvaccines.com Open in urlscan Pro
192.0.66.224 Public Scan

Back to summary

Submitted URL:
https://hcpforipdpeds.com/
Effective URL:
https://www.merckvaccines.com/vaxneuvance-pediatric/
Submission: On December 19 via api (December 19th 2024, 2:05:34 pm UTC) from US — Scanned from DE

Form analysis
1 forms found in the DOM

GET

<form id="searchform" method="get" role="search" aria-label="Site Search">
  <div class="form-group has-search">
    <label for="search" class="screen-reader-text">Search VAXNEUVANCE® Information </label>
    <i class="icon-search form-control-feedback" aria-hidden="true"></i>
    <input type="text" id="search" class="form-control" name="s" value="" oninput="handleInput()" data-event-name="search_click" data-design-module="search" data-design-category="search_term" data-design-label="">
    <i class="icon-close" id="close-icon" onclick="clearSearch()" role="clear" aria-label="Clear Search" data-event-name="search_click" data-design-module="search" data-design-category="search_bar" data-design-label="clear_search"></i>
    <button type="button" id="searchsubmit" aria-label="Search" data-event-name="search_click" data-design-module="search" data-design-category="search_bar" data-design-label="search" disabled="">Search</button>
  </div>
</form>

Text Content

Skip to main content
01. Foundational / Icons / 32x32px/Menu @1x Menu 01. Foundational / Icons /
32x32px/Close @1x Close
Main menu
* Products
* BCG Vaccine U.S.P.
* CAPVAXIVE™

(Pneumococcal 21-valent Conjugate Vaccine)

* ERVEBO®

(Ebola Zaire Vaccine, Live)

* GARDASIL®9

(Human Papillomavirus 9-valent Vaccine, Recombinant)

* M-M-R®II

(Measles, Mumps, and Rubella Virus Vaccine Live)

* PedvaxHIB®

[Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)]

* PNEUMOVAX®23

(Pneumococcal Vaccine Polyvalent)

* ProQuad®

(Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

* RECOMBIVAX HB®

[Hepatitis B Vaccine (Recombinant)]

* RotaTeq®

(Rotavirus Vaccine, Live, Oral, Pentavalent)

* VAQTA®

(Hepatitis A Vaccine, Inactivated)

* VARIVAX®

(Varicella Virus Vaccine Live)

* VAXELIS®

(Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated
Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

* VAXNEUVANCE®

(Pneumococcal 15-valent Conjugate Vaccine)
* Tools & resources
* Tools & resources

Information for your vaccination efforts.

* Vaccination program tools

Resources for your health care setting.

* Patient resources

Credible, patient-centric information about vaccines to help support your
efforts.

* Vaccine office resources

Tools and information for your vaccination program.

* Pharmacy-specific materials

Tips and strategies to proactively engage patients in a vaccination
conversation during pick-up or drop-off.
* Help
* Help home
* My profile and account
* Placing an order
* My product lists
* Order history
* Payments
* Reporting adverse experiences
* DSCSA

Drug Supply Chain Security Act

* Contact us

* News

* Log in

* Sites
* Merck Connect 01. Foundational / Icons / 32x32px/External Link @1x

Practical and patient-centered resources for health care professionals.

* My Merck Accounts 01. Foundational / Icons / 32x32px/External Link @1x

Enroll locations into Merck pricing programs and maintain account and
location information associated with user accounts and organizations.

* Merck Access Program 01. Foundational / Icons / 32x32px/External Link @1x

The Merck Access Program may be able to help answer questions about access
and support.

* MerckHelps™ 01. Foundational / Icons / 32x32px/External Link @1x

Having trouble paying for your Merck medicine? Merck may be able to help.

* Products
* BCG Vaccine U.S.P.
* CAPVAXIVE™

(Pneumococcal 21-valent Conjugate Vaccine)

* ERVEBO®

(Ebola Zaire Vaccine, Live)

* GARDASIL®9

(Human Papillomavirus 9-valent Vaccine, Recombinant)

* M-M-R®II

(Measles, Mumps, and Rubella Virus Vaccine Live)

* PedvaxHIB®

[Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)]

* PNEUMOVAX®23

(Pneumococcal Vaccine Polyvalent)

* ProQuad®

(Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

* RECOMBIVAX HB®

[Hepatitis B Vaccine (Recombinant)]

* RotaTeq®

(Rotavirus Vaccine, Live, Oral, Pentavalent)

* VAQTA®

(Hepatitis A Vaccine, Inactivated)

* VARIVAX®

(Varicella Virus Vaccine Live)

* VAXELIS®

(Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated
Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

* VAXNEUVANCE®

(Pneumococcal 15-valent Conjugate Vaccine)
* Tools & resources
* Tools & resources

Information for your vaccination efforts.

* Vaccination program tools

Resources for your health care setting.

* Patient resources

Credible, patient-centric information about vaccines to help support your
efforts.

* Vaccine office resources

Tools and information for your vaccination program.

* Pharmacy-specific materials

Drug Supply Chain Security Act

* Contact us

* News
* Log in
* Order
* Sites
* Merck Connect 01. Foundational / Icons / 32x32px/External Link @1x

Practical and patient-centered resources for health care professionals.

* My Merck Accounts 01. Foundational / Icons / 32x32px/External Link @1x

Enroll locations into Merck pricing programs and maintain account and
location information associated with user accounts and organizations.

* Merck Access Program 01. Foundational / Icons / 32x32px/External Link @1x

The Merck Access Program may be able to help answer questions about access
and support.

* MerckHelps™ 01. Foundational / Icons / 32x32px/External Link @1x

Having trouble paying for your Merck medicine? Merck may be able to help.

This site is intended for US health care professionals.

ARE YOU A HEALTH CARE PROFESSIONAL?

This section contains information intended for health care professionals in the
United States only and is not intended for the general public.

No, I am not. Please take me back.

Yes, I am.

This site is intended only for residents of the United States, its territories,
and Puerto Rico. Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its
affiliates. All rights reserved.

TERMS AND CONDITIONS
Close
VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine)

* Select safety information
* Prescribing information
* Patient product information

01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons /
32x32px/Close @1x Close Menu
Back
* VAXNEUVANCE home
* Dosage & administration
* Product information
* Recommendations
* Storage & handling
* FAQ
* IPD burden
* Clinical data
* Immunogenicity
* Immune response
* Specific populations
* Safety & tolerability
* Reimbursement
* Resources

* Patient website

* VAXNEUVANCE home
* Dosage & administration
* Product information
* Recommendations
* Storage & handling
* FAQ
* IPD burden
* Clinical data
* Immunogenicity
* Immune response
* Specific populations
* Safety & tolerability
* Reimbursement
* Resources

* Patient website

Search VAXNEUVANCE® Information

Search VAXNEUVANCE® Information Search

To report a side effect or product quality complaint, call 1-800-672-6372

Merck has expanded the scope of its voluntary partial recall to an additional
ten lots of VAXNEUVANCE. Click here for more.

IMMUNOGENICITY MATTERS THROUGH THE FIRST YEAR OF LIFE AND BEYOND TO HELP PROTECT
AGAINST PEDIATRIC IPD—CONSIDER VAXNEUVANCE® (PNEUMOCOCCAL 15-VALENT CONJUGATE
VACCINE)1-5

WHY VAXNEUVANCE?

> Administered as a 4-dose series at 2, 4, 6, and 12 through 15 months of age
>
> Elicited robust immune responses to all 15 serotypes in the vaccine postdose 3
> and postdose 4

MORE REASONS TO CHOOSE VAXNEUVANCE FOR YOUR PEDIATRIC PATIENTS

Protection matters including in the first year of life, when pediatric IPD
incidence is highest4,6-8

Explore IPD burden

The immune response generated postdose 3 is an important measure when evaluating
protection against IPD during the first year of life2,5,9

See immune response

Comparable immune response to PCV13 for 12 shared serotypes and superior immune
responses vs PCV13 for shared Serotype 3 and unique Serotypes 22F and 33Fa

View immunogenicity

Randomized controlled trials assessing the clinical efficacy of VAXNEUVANCE
compared to PCV13 have not been conducted.

default-sum-open-background-color
default-sum-close-background-color
false
default-sum-open-hover-color
default-sum-open-focus-color
default-sum-close-focus-color
.default-sum-close-hover-color

ASTUDY DESIGN

Study 8 was a pivotal, double-blind, active comparator-controlled study in which
participants were randomized to receive VAXNEUVANCE (N=860) or PCV13 (N=860) in
a 4-dose series. The first 3 doses were administered to infants at 2, 4, and 6
months of age and the fourth dose was administered to children at 12 through 15
months of age. Participants also received other licensed pediatric vaccines
concomitantly. Immune responses were measured by IgG response rates, IgG GMCs,
and OPA GMTs for all 15 serotypes contained in VAXNEUVANCE.

> VAXNEUVANCE is CDC, AAP, and AAFP recommended as an option for all of your
> appropriate pediatric patients9-12

AAP, American Academy of Pediatrics; AAFP, American Academy of Family
Physicians; CDC, Centers for Disease Control and Prevention; GMC, geometric mean
concentration (mcg/mL); GMT, geometric mean titer; IgG, Immunoglobulin G; IPD,
invasive pneumococcal disease; OPA, opsonophagocytic activity; PCV13, 13-valent
pneumococcal conjugate vaccine.

Not shown at actual sizeNot shown at actual size

LOOKING TO STOCK VAXNEUVANCE IN YOUR PRACTICE?

Simply register or log into your account to get started.

Order VAXNEUVANCE

VIEW DETAILS ON REIMBURSEMENT

View details on reimbursement

READ FAQ ABOUT VAXNEUVANCE

Read FAQ about VAXNEUVANCE

References

1. Weekly epidemiological record. World Health Organization. 2019;85–104.
Accessed January 26, 2024.
https://www.who.int/publications/i/item/10665-310968
2. Recommendations to assure the quality, safety and efficacy of pneumococcal
conjugate vaccines, Annex 3, TRS No 977. World Health Organization. October
19, 2013. Accessed February 13, 2024.
https://www.who.int/publications/m/item/pneumococcal-conjugate-vaccines-annex3-trs-977
3. Gruber MF, Marshall VB. Chapter 80: Regulation and testing of vaccines in
the US. In: Orenstein WA, Offit PA, Edwards KM, Plotkin SA, eds. Plotkin’s
Vaccines. 8th ed. Elsevier; 2022;1640-1659.e2.
4. Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of
Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 17:
Pneumococcal disease. Centers for Disease Control and Prevention. Last
reviewed May 1, 2024. Accessed August 1, 2024.
https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html
5. Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO
Technical Report Series 1004, Annex 9, 2017. World Health Organization.
Accessed May 28, 2024.
https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9
6. Moraes-Pinto M, Suano-Souza F, Aranda C. Immune system: development and
acquisition of immunological competence. J Pediatr (Rio J). 2021; S59-S66.
doi:10.1016/j.jped.2020.10.006
7. Data available on request from Merck & Co., Inc., Professional
Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify
information package US-PVC-01698.
8. Wodi AP, Morelli V. Epidemiology and Prevention of Vaccine-Preventable
Diseases (Pink Book). 14th edition. Chapter 1: Principles of vaccination.
Centers for Disease Control and Prevention. Last reviewed August 18, 2021.
Accessed January 10, 2024.
https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac.pdf
9. Centers for Disease Control and Prevention. Recommended child and
adolescent immunization schedule for ages 18 years or younger, United
States 2024. Updated June 27, 2024. Accessed August 23, 2024.
https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
10. Immunizations. American Academy of Pediatrics. Last updated June 24, 2024.
Accessed July 4, 2024. https://www.aap.org/en/patient-care/immunizations
11. Immunization schedules. American Academy of Family Physicians. 2024.
Accessed May 8, 2024.
https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/immunization-schedules.html
12. Farrar J, Gierke R, Andrejko K, et al. ACIP updates: recommendations for
use of 20-valent pneumococcal conjugate vaccine in children ― United
States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:1072. doi:
10.15585/mmwr.mm7239a5

ExternalSitePopup

BY CLICKING ON THIS LINK, YOU WILL BE LEAVING MERCK VACCINES.

Cancel
Proceed
Cancel
Proceed

INDICATIONS AND USAGE

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active
immunization for the prevention of invasive disease caused by Streptococcus
pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F,
and 33F in individuals 6 weeks of age and older.

SELECT SAFETY INFORMATION

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to
individuals with a severe allergic reaction (eg, anaphylaxis) to any component
of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving
immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

Apnea following intramuscular vaccination has been observed in some infants born
prematurely. Vaccination of premature infants should be based on the infant’s
medical status and the potential benefits and possible risks.

The most commonly reported solicited adverse reactions in children vaccinated at
2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose
series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%),
injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased
appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%),
injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to
13.4%).

The most commonly reported solicited adverse reactions in children 2 through 17
years of age vaccinated with a single dose were: injection-site pain (54.8%),
myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema
(19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration
(6.8%).

The reported solicited adverse reactions in children 7 through 11 months of age
who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability
(32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site
swelling (18.8%), injection-site pain (18.8%), injection-site induration
(17.2%), decreased appetite (15.6%), and urticaria (1.6%).

The reported solicited adverse reactions in children 12 through 23 months of age
who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability
(35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite
(22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and
injection-site induration (8.1%).

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

Before administering VAXNEUVANCE, please read the accompanying Prescribing
Information. The Patient Information also is available.

BY CLICKING ON THIS LINK, YOU WILL BE LEAVING THIS SITE.

This link will take you to a site outside Merck & Co., Inc.

Merck does not review or control the content of any non-Merck site. Merck does
not endorse and is not responsible for the accuracy, content, practices, or
standards of any non-Merck site.

Cancel Proceed
Cancel Proceed
TERMS AND CONDITIONS
Close

HELPFUL LINKS

* Supply status
* Prime distributors
* Return merchandise
* Shipping schedule
* Storage and handling
* Disaster relief returns program
* Packaging information guide
* DSCSA T3 data
* Ordering
* Informational links
* Terms & conditions of sale
* Reimbursement codes

* Supply status
* Prime distributors
* Return merchandise
* Shipping schedule

* Storage and handling
* Disaster relief returns program
* Packaging information guide
* DSCSA T3 data

* Ordering
* Informational links
* Terms & conditions of sale
* Reimbursement codes

Additional Merck sites

* My Merck Accounts
* Merck Connect

Merck Vaccine Customer Center

877.VAX.MERCK (877.829.6372)

View more contact options

* Site map
* Privacy policy
* Terms of use
* Cookie preferences
* Accessibility
* Your Privacy Choices
* Consumer Health Data Privacy Policy

This site is intended only for residents of the United States and its
territories, including Puerto Rico. US-PVC-01860 10/24

no
no
no

INDICATIONS AND USAGE INDICATIONS AND USAGE

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active
immunization for the prevention of invasive disease caused by Streptococcus
pneumoniae[ Read more ]

SELECT SAFETY INFORMATION SELECT SAFETY INFORMATION

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to
individuals with a severe allergic reaction (eg, anaphylaxis) to any component
of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving
immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

Before administering VAXNEUVANCE, please read the accompanying Prescribing
Information. The Patient Information also is available.

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to
individuals with a severe allergic reaction (eg, anaphylaxis) to any component
of VAXNEUVANCE or[ Read more ]

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to
individuals with a severe allergic reaction (eg, anaphylaxis) to any component
of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving
immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.[
Read more ]

We and our business partners use cookies and tracking technologies for
personalization, advertising, and monitoring according to ourGlobal Online
Tracking Policy andUS Privacy Notice. By continuing or accepting below, you ask
us to use and share your data for these purposes. You can also “Reject All
Optional Cookies” ormanage specific preferences.
Reject All Optional Cookies Accept All Optional Cookies

www.merckvaccines.com Open in urlscan Pro 192.0.66.224 Public Scan

Form analysis 1 forms found in the DOM

GET

Text Content

www.merckvaccines.com Open in urlscan Pro
192.0.66.224 Public Scan

Form analysis
1 forms found in the DOM